By Iain Gilbert
Date: Friday 08 Aug 2025
(Sharecast News) - Drugmaker GSK said on Friday that it had reached a settlement, alongside CureVac, to resolve long-running patent litigation with BioNTech and Pfizer over mRNA-based COVID-19 vaccines.
CureVac/BioNTech mRNA patent litigation settlement | 08-Aug-2025 | 07:00 | RNS |
Transaction in Own Shares | 08-Aug-2025 | 07:00 | RNS |
Transaction in Own Shares | 07-Aug-2025 | 07:00 | RNS |
Transaction in Own Shares | 06-Aug-2025 | 07:00 | RNS |
Transaction in Own Shares | 05-Aug-2025 | 07:00 | RNS |
GSK profits lifted by strong cancer drug sales | 30-Jul-2025 | Times |
GlaxoSmithKline scraps sale of old drugs | 05-Dec-2014 | Telegraph |
Glaxo sharpens axe to save £1bn as insurers and ... | 01-Dec-2014 | The Independent |
GSK to cut hundreds of US jobs | 01-Dec-2014 | Telegraph |
Ebola vaccine trials 'encouraging', says GSK | 27-Nov-2014 | Telegraph |
Questor :GlaxoSmithKline | 16-Apr-2014 | Telegraph |
Questor:GlaxoSmithKline | 06-Oct-2011 | Telegraph |
Questor:GlaxoSmithKline | 11-Aug-2011 | Telegraph |
Questor tip: GlaxoSmithKline | 28-Jul-2011 | Telegraph |
Investment Column: GlaxoSmithKline | 27-Jul-2011 | The Independent |
Currency | UK Pounds |
Share Price | 1,395.50p |
Change Today | 12.50p |
% Change | 0.90 % |
52 Week High | 1,671.00 |
52 Week Low | 1,264.00 |
Volume | 5,055,776 |
Shares Issued | 4,075.84m |
Market Cap | £56,878m |
RiskGrade | 129 |
Value | ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth | ![]() |
---|
Strong Buy | 3 |
Buy | 2 |
Neutral | 14 |
Sell | 3 |
Strong Sell | 1 |
Total | 23 |
Latest | Previous | |
---|---|---|
Q2 | Q1 | |
Ex-Div | 14-Aug-25 | 15-May-25 |
Paid | 09-Oct-25 | 10-Jul-25 |
Amount | 16.00p | 16.00p |
Time | Volume / Share Price |
16:18 | 13 @ 1,398.50p |
16:13 | 1 @ 1,399.50p |
16:13 | 1 @ 1,400.00p |
16:06 | 1 @ 1,401.00p |
16:52 | 1,286 @ 1,395.50p |
You are here: research